Luye Pharma Group Stock Buy Hold or Sell Recommendation
| LYPHF Stock | USD 0.34 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Luye Pharma Group is 'Strong Sell'. Macroaxis provides Luye Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LYPHF positions.
Check out Luye Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Luye and provide practical buy, sell, or hold advice based on investors' constraints. Luye Pharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Luye |
Execute Luye Pharma Buy or Sell Advice
The Luye recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Luye Pharma Group. Macroaxis does not own or have any residual interests in Luye Pharma Group or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Luye Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Luye Pharma Trading Alerts and Improvement Suggestions
| Luye Pharma Group has some characteristics of a very speculative penny stock | |
| Luye Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.2 B. Net Loss for the year was (134.39 M) with profit before overhead, payroll, taxes, and interest of 3.4 B. | |
| About 35.0% of the company outstanding shares are owned by corporate insiders |
Luye Pharma Returns Distribution Density
The distribution of Luye Pharma's historical returns is an attempt to chart the uncertainty of Luye Pharma's future price movements. The chart of the probability distribution of Luye Pharma daily returns describes the distribution of returns around its average expected value. We use Luye Pharma Group price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Luye Pharma returns is essential to provide solid investment advice for Luye Pharma.
| Mean Return | 0.15 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 1.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Luye Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Luye Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Luye Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Luye Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Luye pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 1.21 | |
Ir | Information ratio | 0.01 |
Luye Pharma Volatility Alert
Luye Pharma Group exhibits very low volatility with skewness of 8.12 and kurtosis of 66.0. Luye Pharma Group is a potential penny stock. Although Luye Pharma may be in fact a good instrument to invest, many penny pink sheets are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Luye Pharma Group. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Luye instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Luye Pharma Fundamentals Vs Peers
Comparing Luye Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Luye Pharma's direct or indirect competition across all of the common fundamentals between Luye Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Luye Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Luye Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Luye Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Luye Pharma to competition |
| Fundamentals | Luye Pharma | Peer Average |
| Return On Equity | -0.0261 | -0.31 |
| Return On Asset | 0.0081 | -0.14 |
| Profit Margin | (0.04) % | (1.27) % |
| Operating Margin | 0.06 % | (5.51) % |
| Current Valuation | 2.08 B | 16.62 B |
| Shares Outstanding | 3.55 B | 571.82 M |
| Shares Owned By Insiders | 35.41 % | 10.09 % |
| Shares Owned By Institutions | 24.08 % | 39.21 % |
| Price To Book | 2.17 X | 9.51 X |
| Price To Sales | 0.47 X | 11.42 X |
| Revenue | 5.2 B | 9.43 B |
| Gross Profit | 3.4 B | 27.38 B |
| EBITDA | 324.9 M | 3.9 B |
| Net Income | (134.39 M) | 570.98 M |
| Total Debt | 4.21 B | 5.32 B |
| Debt To Equity | 1.15 % | 48.70 % |
| Current Ratio | 1.46 X | 2.16 X |
| Book Value Per Share | 2.54 X | 1.93 K |
| Cash Flow From Operations | 182.37 M | 971.22 M |
| Earnings Per Share | 0.03 X | 3.12 X |
| Number Of Employees | 4.8 K | 18.84 K |
| Beta | 0.93 | -0.15 |
| Market Capitalization | 2.66 B | 19.03 B |
| Total Asset | 22.58 B | 29.47 B |
| Annual Yield | 0.02 % | |
| Net Asset | 22.58 B |
Luye Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Luye . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Luye Pharma Buy or Sell Advice
When is the right time to buy or sell Luye Pharma Group? Buying financial instruments such as Luye Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Luye Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Luye Pink Sheet
Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.